Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 446

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 446
---
2024. On October9, 2024, the Company and certain existing warrant holders entered into warrant amendment agreements, or collectively, the October Warrant Amendment, to amend those warrants issued by Company to such holders, collectively, to purchase up to 105,843 NLS Common Shares issued to such holders, or the Existing Warrants. The October Warrant Amendment makes certain adjustment to the definition of a “Fundamental Transaction” in Section 3(e) of the Existing Warrants. In exchange for the Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.80 and issued to the holders Pre -FundedWarrants to purchase up to 136,648 NLS Common Shares, or the October Pre -FundedWarrants. Each October Pre -FundedWarrant is exercisable for one Common Share at an exercise price of CHF 0.80 per share. The October Pre -FundedWarrants are immediately exercisable and may be exercised at any time until all of the October Pre -FundedWarrants are exercised in full. On October 10, 2024, the Company successfully implemented a restructuring measure by converting the claims of related party debt holders in the amount of $2,788,650 into 493,986 NLS Common Shares. This conversion was facilitated through an ordinary capital increase, providing the necessary shares for the debt holders, and was recorded at fair market value with no gain or loss recognized in the statement of operations. On December4, 2024, we entered into a securities purchase agreement with an accredited investor, providing for the issuance in a private placement offering of 322,580 registered NLS Common Shares, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1million. The offering was structured in two tranches, with the first tranche of $500,000 closing in January 2025 following shareholder approval. The proceeds from the offering were intended to support our general corporate purposes and our proposed Merger with Kadimastem. The second tranche of $500,000 may occur, at the election of the investor, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the NLS Common Shares trading for at least ten consecutive trading days above the purchase price of $3.10, which corresponds to an approximate 15% premium. As of July 9, 2025, the condition for the second tranche has not